SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 23.25 |
Enterprise Value ($M) | -53.06 |
Book Value ($M) | 86.20 |
Book Value / Share | 1.29 |
Price / Book | 0.27 |
NCAV ($M) | 47.91 |
NCAV / Share | 0.71 |
Price / NCAV | 0.49 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.73 |
Return on Assets (ROA) | -0.46 |
Return on Equity (ROE) | -1.00 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 5.50 |
Current Ratio | 5.50 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 192.90 |
Assets | 231.20 |
Liabilities | 144.99 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 19.89 |
Operating Income | -79.19 |
Net Income | -131.67 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -88.56 |
Cash from Investing | 94.53 |
Cash from Financing | 0.25 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Fmr Llc | 6.90 | -13.57 | |
13G/A | Bb Biotech Ag | 5.00 | -8.24 | |
13G/A | Price T Rowe Associates Inc /md/ | 14.00 | 35.02 | |
13G | BlackRock, Inc. | 5.10 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
85,220 | 387,612 | 21.99 | |
103,330 | 361,385 | 28.59 | |
179,763 | 497,418 | 36.14 | |
152,393 | 629,843 | 24.20 | |
(click for more detail) |
Similar Companies | |
---|---|
EXEL – Exelixis, Inc. | FDMT – 4D Molecular Therapeutics, Inc. |
FGEN – FibroGen, Inc. | GERN – Geron Corporation |
GILD – Gilead Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io